Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study - PubMed (original) (raw)

Clinical Trial

Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study

Jarred Younger et al. Pain Med. 2009 May-Jun.

Abstract

Objective: Fibromyalgia is a chronic pain disorder that is characterized by diffuse musculoskeletal pain and sensitivity to mechanical stimulation. In this pilot clinical trial, we tested the effectiveness of low-dose naltrexone in treating the symptoms of fibromyalgia.

Design: Participants completed a single-blind, crossover trial with the following time line: baseline (2 weeks), placebo (2 weeks), drug (8 weeks), and washout (2 weeks).

Patients: Ten women meeting criteria for fibromyalgia and not taking an opioid medication.

Interventions: Naltrexone, in addition to antagonizing opioid receptors on neurons, also inhibits microglia activity in the central nervous system. At low doses (4.5 mg), naltrexone may inhibit the activity of microglia and reverse central and peripheral inflammation.

Outcome measures: Participants completed reports of symptom severity everyday, using a handheld computer. In addition, participants visited the lab every 2 weeks for tests of mechanical, heat, and cold pain sensitivity.

Results: Low-dose naltrexone reduced fibromyalgia symptoms in the entire cohort, with a greater than 30% reduction of symptoms over placebo. In addition, laboratory visits showed that mechanical and heat pain thresholds were improved by the drug. Side effects (including insomnia and vivid dreams) were rare, and described as minor and transient. Baseline erythrocyte sedimentation rate predicted over 80% of the variance in drug response. Individuals with higher sedimentation rates (indicating general inflammatory processes) had the greatest reduction of symptoms in response to low-dose naltrexone.

Conclusions: We conclude that low-dose naltrexone may be an effective, highly tolerable, and inexpensive treatment for fibromyalgia.

PubMed Disclaimer

Figures

Figure 1

Overall, self-reported, daily fibromyalgia symptoms (scale 0–100, with 100 being most severe) as a function of placebo and low-dose naltrexone administration. Sections are: baseline, placebo, drug, and washout. A 3-day smoothing has been applied. (A) Data from all participants (N = 10). (B) Data separated by drug responders (30% or greater reduction of symptoms over placebo; solid line, N = 6) and nonresponders (broken line, N = 4).

Figure 2

Changes in pain threshold at laboratory sessions during baseline (visits 1 and 2), placebo (visit 3), drug (visits 4–7), and washout (visit 8) phases. (A) Mechanical pain threshold; baseline is 1.02 kg/cm2. (B) Thermal pain threshold; baseline is 37.9°C.

Figure 3

Relationship between drug response (reduction of fibromyalgia symptoms in the drug condition) and baseline erythrocyte sedimentation rate.

Cited by

Reported Benefits of Low-Dose Naltrexone Appear to Be Independent of the Endogenous Opioid System Involving Proopiomelanocortin Neurons and β-Endorphin.
Metz MJ, Daimon CM, Hentges ST. Metz MJ, et al. eNeuro. 2021 Jun 16;8(3):ENEURO.0087-21.2021. doi: 10.1523/ENEURO.0087-21.2021. Print 2021 May-Jun. eNeuro. 2021. PMID: 34031099 Free PMC article.
Treatment of Complex Regional Pain Syndrome (CRPS) using low dose naltrexone (LDN).
Chopra P, Cooper MS. Chopra P, et al. J Neuroimmune Pharmacol. 2013 Jun;8(3):470-6. doi: 10.1007/s11481-013-9451-y. Epub 2013 Apr 2. J Neuroimmune Pharmacol. 2013. PMID: 23546884 Free PMC article.
Glia and Orofacial Pain: Progress and Future Directions.
Ye Y, Salvo E, Romero-Reyes M, Akerman S, Shimizu E, Kobayashi Y, Michot B, Gibbs J. Ye Y, et al. Int J Mol Sci. 2021 May 19;22(10):5345. doi: 10.3390/ijms22105345. Int J Mol Sci. 2021. PMID: 34069553 Free PMC article. Review.
Milnacipran for the Treatment of Fibromyalgia.
Gupta H, Girma B, Jenkins JS, Kaufman SE, Lee CA, Kaye AD. Gupta H, et al. Health Psychol Res. 2021 Jul 10;9(1):25532. doi: 10.52965/001c.25532. eCollection 2021. Health Psychol Res. 2021. PMID: 34746490 Free PMC article. Review.
Low-dose naltrexone for the treatment of fibromyalgia: protocol for a double-blind, randomized, placebo-controlled trial.
Bruun KD, Amris K, Vaegter HB, Blichfeldt-Eckhardt MR, Holsgaard-Larsen A, Christensen R, Toft P. Bruun KD, et al. Trials. 2021 Nov 15;22(1):804. doi: 10.1186/s13063-021-05776-7. Trials. 2021. PMID: 34781989 Free PMC article.

References

1. Nuemann L, Buskila D. Epidemiology of fibromyalgia. Curr Pain Headache Rep. 2003;7:362–368. - PubMed
1. White KP, Speechley M, Harth M, et al. The London fibromyalgia study: The prevalence of fibromyalgia syndrome in London, Ontario. J Rheumatol. 1999;26:1570–1576. - PubMed
1. Yunus MB. Towards a model of pathophysiology of fibromyalgia: Aberrant central pain mechanisms with peripheral modulation. J Rheumatol. 1992;19:846–850. - PubMed
1. Waylonis GW, Heck W. Fibromyalgia syndrome. New associations. Am J Phys Med Rehabil. 1992;71:343–348. - PubMed
1. Kaplan KH, Goldenberg DL, Galvin-Nadeau M. The impact of a meditation-based stress reduction program on fibromyalgia. Gen Hosp Psychiatry. 1993;15:284–289. - PubMed

Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study - PubMed (original) (raw)